ArticleAmerican journal of translational research2026
Impact of sacubitril/valsartan on cardiac structure and function in post-acute myocardial infarction heart failure patients aged over 65: a single-center experience.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study evaluates the impact of sacubitril/valsartan on cardiac structure and function in post- acute myocardial infarction (AMI) heart failure (HF) patients over 65 years.
methodsA retrospective analysis was conducted on 204 HF patients over 65 years who experienced AMI between January 2018 and December 2023. Patients were divided into two groups: sacubitril/valsartan treatment group (n = 103) and enalapril treatment group (n = 101). Baseline characteristics were comparable between the two groups. Echocardiographic evaluations, six-minute walk tests, treatment effects, adverse reactions, and patient satisfaction were assessed over a one-year follow-up period.
resultsThe sacubitril/valsartan group had bigger decreases in NT-proBNP (P < 0.001) and cTnI (P = 0.030). The sacubitril/valsartan group demonstrated significant improvements in left ventricular ejection fraction (LVEF) (P = 0.002), reduced left ventricular end-diastolic volume (LVEDV) (P = 0.019), and left ventricular end-systolic volume (LVESV) (P = 0.002) when compared to the enalapril group. A substantial increase in six-minute walk test distance was observed in the sacubitril/valsartan group (P = 0.013). The treatment was significantly more effective in the sacubitril/valsartan group compared to the enalapril group (51.46% v.s. 30.69%, P = 0.011). Patient satisfaction was also higher in the sacubitril/valsartan group (P = 0.043).
conclusionSacubitril/valsartan shows superior efficacy over enalapril in improving cardiac structure, function, exercise capacity, and patient satisfaction in elderly post-AMI HF patients, as evidenced by greater improvements in cardiac function and more pronounced reduction in stress-related biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.